Loading…
← CockpitCompetitor Analysis › TMDX TransMedics Group, Inc.Open in the cockpit ↗

TransMedics Group, Inc.TMDXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of the Organ Care System, a portable device that keeps donor organs warm and functioning during transport for transplant.

Momentum leader 92
Mkt cap
$3.35B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$100M
20-day average traded
Fwd P/E
43.4×
forward earnings
ROIC−WACC
-6.2 pp
WACC 13.6%
Hurdle
-50 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$96.43
1D+2.7%
1W+4.8%
1M+29.0%
3M+6.1%
6M+41.8%
YTD-20.7%
1Y-15.0%
ATR %5.2%
Beta1.16
52w lowhigh38.2% off high

What TransMedics does

Maker of the Organ Care System, a portable device that keeps donor organs warm and functioning during transport for transplant.

Earns per transplant: a hospital pays for the single-use organ kit and for a bundled service in which TransMedics' own surgeons, pilots and aircraft retrieve the organ and fly it back. That service side has grown into a large part of what it bills, which is why it has bought its own planes.

Products and services

  • OCS Heart
  • OCS Lung
  • OCS Liver
  • Organ logistics/transport services (NOP)

Customers

  • Transplant centers
  • Surgeons

Where it sits in the supply chain

  • Medical devices
  • Organ transplant logistics
  • Ex-vivo organ perfusion & transport

What could go right

  • Transplant volume growth via extended organ viability
  • Logistics/service revenue growth

What could go wrong

  • Regulatory/reimbursement risk
  • Competitive perfusion technology entrants

Moat: narrow (IP / patents, regulatory licence, installed base). Patented warm-perfusion technology plus its own logistics network expand usable donor organs, hard to replicate quickly.

Headquarters: Andover, Massachusetts · Founded: 1998 · Employees: 898

Named competitors

TransMedics at a glance

Size TransMedics (TMDX) is a United States Health Care company (Medical Specialties) with a market value of $3.35B, the 1467th largest of 3,085 United States companies the cockpit tracks. Shares closed at $96.43 on 18 Nov 2026.

Performance Over six months the shares gained 41.8%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 28.5% over the last twelve months (peer median +5.7%); the operating margin is 12.0% (peer median 7.3%).

Valuation It trades at 43.4× forward earnings against a peer median of 25.1× (5th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +88%, so the hurdle is -50 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.2 points below its cost of capital (13.6% WACC).

Credit TransMedics has 1 bond outstanding ($460M).

Short interest Short interest is 25.6% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026TMDX 140Peer median 104
Six months, rebased to 100: TransMedics against the median of its 20 peers (local-currency closes).

TransMedics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$728M$605M$442M$242M$93.5M
Revenue growth—+37%+83%+159%—
Gross profit$416M$363M$262M$154M$65.3M
EBITDA$128M$136M$57.3M$8.76M-$27.2M
Net income$144M$190M$35.5M-$25.0M-$36.2M
Free cash flow$44.7M$134M-$80.9M-$165M-$57.7M
Capital expenditure$67.7M$59.3M$130M$179M$11.9M
Total debt$867M$519M$518M$516M$67.6M

Quarterly statements and history in the cockpit →

TransMedics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%603658PLSE688301AXGN603301AMBU-B4203300003IRTCAFXTECN6030146881141SXPNVST002432CDNAFIEATRCCOTNTMDX6-month return →1-month return →
Up and to the right = strong over both horizons. TransMedics is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×100×200×603658688301AXGN603301AMBU-B4203300003IRTCTECNNVST002432CDNAATRCTMDXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TransMedics is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%603658AXGN603301AMBU-B300003IRTCTECN6030146881141SXP002432FIETMDXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. TransMedics is the large dot.

TransMedics competitors and peer comparison

Head to head with its named competitors (TMDX vs XVIVO.ST vs GETI-B.ST vs 4543.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
TransMedics TMDX$3.35B+42%+28%12%43.4×38.4%
Xvivo Perfusion XVIVO.ST$611M-32%+18%12%53.1×35.9%
Getinge GETI-B.ST$7.45B+40%-4%14%21.1×5.0%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%

How TransMedics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TransMedics against its 20 peers (data as of 18 Nov 2026)
MeasureTMDXPeer medianRank in peer set
1-month return+29.0%-0.2%2nd highest of 21
6-month return+41.8%+3.2%5th highest of 21
Distance from 52-week high-38.2%-22.1%6th lowest of 21
Revenue growth (TTM)+28.5%+5.7%4th highest of 21
Operating margin12.0%7.3%8th highest of 20
Forward P/E43.4×25.1×5th most expensive of 19
Growth the price implies (Req g, 7 yrs)38.4%11.3%6th most demanding of 17
Growth delivered (Del g)+88.2%+8.5%highest of 17
Hurdle (Req g minus delivered)-49.8 pp+1.7 ppleast demanding of 17
ROIC minus cost of capital-6.2 pp-1.1 pp4th lowest of 19
EV / EBITDA29.2×16.3×5th most expensive of 11
Net debt / EBITDA2.9×0.1×most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a

TransMedics bonds and credit

TransMedics has 1 bond outstanding with $460M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are TransMedics's main competitors?
Named competitors: XVIVO Perfusion (XVIVO.ST), Getinge (GETI-B.ST), Terumo (4543.T). The cockpit's measured peer set (industry) also includes Autobio Diagnostics (603658.SS), Pulse Biosciences (PLSE), iRay Technology (688301.SS), Axogen (AXGN), Zhende Medical (603301.SS), Ambu A/S (AMBU-B.CO).
Is TransMedics expensive compared with its peers?
On forward p/e it trades at 43.4× against a peer median of 25.1×, 5th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +88%, so the hurdle is -50 pp: the price already allows for a slowdown.
How has TransMedics stock performed?
Over six months to 18 Nov 2026 the shares returned +41.8% against +3.2% for the median peer; over one year -15.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.